AMY GOODPASTER: Open Payments
NPI 1518639640 · CARMEL, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,126 in 61 payments from 17 companies in 2025. Trend: 2023 $854 · 2024 $1,037 · 2025 $1,126
Food & beverage: $1,126
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $268 |
| Axsome Therapeutics, Inc. | 6 | $184 |
| Novo Nordisk Inc | 11 | $168 |
| Lilly USA, LLC | 4 | $66 |
| Astellas Pharma US Inc | 3 | $58 |
| Alexion Pharmaceuticals, Inc. | 2 | $56 |
| Amgen Inc. | 3 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Neos Therapeutics, LP | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $35 |
Products named: Auvelity, UBRELVY, Ozempic, VRAYLAR, MOUNJARO, Veozah, STRENSIQ, Wegovy.
Industry payments across IN — which companies pay providers there.
